US visitors, please note: This website contains information on the PROGENSA® PCA3 Assay which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or applicable in the USA. View details on US FDA approval for PROGENSA® PCA3 Assay.
Engmaschige Überwachung des Prostatakrebses ohne aktive Behandlung, bis der Tumor fortschreitet (basierend auf dem Prostata-spezifischen Antigen (PSA) und/oder Prostatakrebsgen 3 (PCA3)-Überwachung, Symptomentwicklung etc.)